The recently introduced Total Thrombus-Formation Analysis System (T-TAS), is a microchip-based flow chamber system designed to evaluate thrombogenicity in whole blood.
As Hart Biologicals celebrates its 10th anniversary since moving into its current headquarters location at Rivergreen Business Centre on the outskirts of Hartlepool, much has changed since those early days in September 2009.
Sales Manager, Paul Bates, reviews the benefits of both point of care testing and laboratory testing.
Hart Biologicals has announced the availability of its new Ristocetin MEA Test kit.
Hart Biologicals recently showcased an innovative product at the UK NEQAS for Blood Coagulation Clinical and Laboratory Haemostasis meeting at Sheffield Hallam University.
Hart Biologicals is getting ready to present at this year’s UK NEQAS at Sheffield Hallam Universityand will be bringing along one of its latest products, the T-TAS 01.
A rebooted Hart Biologicals website has improved the online experience for its users.
As part of its continuing product development programme, Hart Biologicals is pleased to announce the availability of a new range of platelet aggregation reagents specifically designed for use with whole blood samples using Multiple Electrode Aggregometry (MEA) systems.
For the past four years Hart Biologicals, specialists in haemostasis and in vitro diagnostics, has been working alongside one woman with a unique set of requirements.
As part of its continuing product improvement programme Hart Biologicals is making further changes to its (HB-4452-FG) PT/INR Line Set.
Hart Biologicals, the haematology and thrombosis specialist, has been successful in placing its Thrombistat MC1WB systems in a strategic location in the South East of England.
Managing Director of Hart Biologicals, Alby Pattison MBE gives his opinion on current thinking towards DOAC and Warfarin.